Targeted Therapy for METex14-Mutated NSCLC
An overview of recent FDA breakthrough therapy designations for the MET inhibitors capmatinib and tepotinib as new treatment options for patients with MET exon 14–mutated non–small cell lung cancer.
An overview of recent FDA breakthrough therapy designations for the MET inhibitors capmatinib and tepotinib as new treatment options for patients with MET exon 14–mutated non–small cell lung cancer.
Certepetide plus gemcitabine and nab-paclitaxel showed antitumor activity despite failing to improve PFS vs chemotherapy alone in untreated metastatic pancreatic cancer.
Pelareorep plus modified FOLFIRINOX with or without atezolizumab showed acceptable safety in newly diagnosed metastatic pancreatic ductal adenocarcinoma.
Intraperitoneal and intravenous paclitaxel plus S-1 improved OS over intravenous paclitaxel and S-1 alone in gastric cancer with peritoneal metastasis.
Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.
First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.
Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Dr Bardia discusses the significance of the FDA approval of Dato-DXd, and pivotal findings from the phase 3 TROPION-Breast01 trial that led to the approval.